title: Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation.
abstract: Evidence suggests inhibition of leukocyte trafficking mitigates, in part, ozone-induced inflammation. In the present study, the authors postulated that inhibition of myristoylated alanine-rich C kinase substrate (MARCKS), an 82-kDa protein with multiple biological roles, could inhibit ozone-induced leukocyte trafficking and cytokine secretions. BALB/c mice (n = 5/cohort) were exposed to ozone (100 ppb) or forced air (FA) for 4 hours. MARCKS-inhibiting peptides, MANS, BIO-11000, BIO-11006, or scrambled control peptide RNS, were intratracheally administered prior to ozone exposure. Ozone selectively enhanced bronchoalveolar lavage (BAL) levels of killer cells (KCs; 6 +/- 0.9-fold), interleukin-6 (IL-6; 12.7 +/- 1.9-fold), and tumor necrosis factor (TNF; 2.1 +/- 0.5-fold) as compared to cohorts exposed to FA. Additionally, ozone increased BAL neutrophils by 21% +/- 2% with no significant (P > .05) changes in other cell types. MANS, BIO-11000, and BIO-11006 significantly reduced ozone-induced KC secretion by 66% +/- 14%, 47% +/- 15%, and 71.1% +/- 14%, and IL-6 secretion by 69% +/- 12%, 40% +/- 7%, and 86.1% +/- 11%, respectively. Ozone-mediated increases in BAL neutrophils were reduced by MANS (86% +/- 7%) and BIO-11006 (84% +/- 2.5%), but not BIO-11000. These studies identify for the first time the novel potential of MARCKS protein inhibitors in abrogating ozone-induced increases in neutrophils, cytokines, and chemokines in BAL fluid. BIO-11006 is being developed as a treatment for chronic obstructive pulmonary disorder (COPD) and is currently being evaluated in a phase 2 clinical study.
authors.affiliation: Airways Biology Initiative, Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania, 125 South 31st Street, Philadelphia, PA 19104-3403, USA.
authors.forename: Gautam
authors.initials: G
authors.lastname: Damera
authors.forename: William F
authors.initials: WF
authors.lastname: Jester
authors.forename: Meiqi
authors.initials: M
authors.lastname: Jiang
authors.forename: Hengjiang
authors.initials: H
authors.lastname: Zhao
authors.forename: Homer W
authors.initials: HW
authors.lastname: Fogle
authors.forename: Michael
authors.initials: M
authors.lastname: Mittelman
authors.forename: Angela
authors.initials: A
authors.lastname: Haczku
authors.forename: Edwin
authors.initials: E
authors.lastname: Murphy
authors.forename: Indu
authors.initials: I
authors.lastname: Parikh
authors.forename: Reynold A
authors.initials: RA
authors.lastname: Panettieri
mesh_terms: D000818:Animals; D001991:Bronchitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D051379:Mice; D008807:Mice, Inbred BALB C; D000076250:Myristoylated Alanine-Rich C Kinase Substrate; D020556:Neutrophil Infiltration / Q000187:drug effects*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016207:Cytokines; D047908:Intracellular Signaling Peptides and Proteins; C000619711:Marcks protein, mouse; D008565:Membrane Proteins; D010455:Peptides; D000076250:Myristoylated Alanine-Rich C Kinase Substrate